Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1183/13993003.04015-2020 http://scihub22266oqcxt.onion/10.1183/13993003.04015-2020 33574080!7877327!33574080     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33574080&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Eur+Respir+J 2021 ; 58 (3): ? Nephropedia Template TP {{tp|p=33574080|t=2021. Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life |pdf=|usr=}}{{33574080}} gab.com Text Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life JO: Eur Respir J http://www.kidney.de/pget.php?&tw=1&pmid=33574080 #FOAvip BACKGROUND: Coronavirus disease 2019 (COVID-19) has spread worldwide, having a dramatic impact on healthcare systems. The aim of this study is to evaluate mid-term clinical impact of COVID-19 on respiratory function. METHODS: 379 patients were evaluated 4 months after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnosis. Patients were divided in two groups based on the presence of pneumonia during COVID-19. Clinical conditions, quality of life, symptomatology, 6-min walk test, pulmonary function test with spirometry and diffusing capacity of the lung for carbon monoxide were analysed. Data were compared to clinical evolution during COVID-19 (development of acute respiratory distress syndrome, need of invasive mechanical ventilation, partial oxygen saturation (S (pO(2)) )/inspiratory oxygen fraction (F (IO(2)) ) ratio and pneumonia severity index (PSI)). RESULTS: After a median 135 days, 260 (68.6%) out of 379 patients referred at least one symptom. Patients who developed pneumonia during COVID-19 showed lower S (pO(2)) at rest (p<0.001), S (pO(2)) during 6-min walk test (p<0.001), total lung capacity (p<0.001), airway occlusion pressure after 0.1 s (P (0.1)) (p=0.02), P (0.1)/maximal inspiratory pressure ratio (p=0.005) and higher Borg category-ratio scale (p=0.006) and modified Medical Research Council breathlessness scale (p=0.003), compared to patients without pneumonia. S (pO(2)) /F (IO(2)) ratio and PSI during SARS-CoV-2 pneumonia were directly associated with mid-term alteration of S (pO(2)) at rest (p<0.001) and during 6-min walk test (p<0.001), residual volume (p<0.001), total lung capacity (p<0.001 and p=0.003, respectively) and forced vital capacity (p=0.004 and p=0.03, respectively). CONCLUSION: Lung damage during COVID-19 correlates to the reduction of pulmonary function 4 months after acute infection. Twit Text FOAVip Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life ????Eur Respir J http://www.kidney.de/pget.php?&tw=1&pmid=33574080 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33574080 #FOAvip English Wikipedia <ref>{{Cite pmid|33574080}}</ref> Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life #MMPMID33574080 Anastasio F; Barbuto S; Scarnecchia E; Cosma P; Fugagnoli A; Rossi G; Parravicini M; Parravicini P Eur Respir J 2021[Sep]; 58 (3): ? PMID33574080show ga BACKGROUND: Coronavirus disease 2019 (COVID-19) has spread worldwide, having a dramatic impact on healthcare systems. The aim of this study is to evaluate mid-term clinical impact of COVID-19 on respiratory function. METHODS: 379 patients were evaluated 4 months after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnosis. Patients were divided in two groups based on the presence of pneumonia during COVID-19. Clinical conditions, quality of life, symptomatology, 6-min walk test, pulmonary function test with spirometry and diffusing capacity of the lung for carbon monoxide were analysed. Data were compared to clinical evolution during COVID-19 (development of acute respiratory distress syndrome, need of invasive mechanical ventilation, partial oxygen saturation (S (pO(2)) )/inspiratory oxygen fraction (F (IO(2)) ) ratio and pneumonia severity index (PSI)). RESULTS: After a median 135 days, 260 (68.6%) out of 379 patients referred at least one symptom. Patients who developed pneumonia during COVID-19 showed lower S (pO(2)) at rest (p<0.001), S (pO(2)) during 6-min walk test (p<0.001), total lung capacity (p<0.001), airway occlusion pressure after 0.1 s (P (0.1)) (p=0.02), P (0.1)/maximal inspiratory pressure ratio (p=0.005) and higher Borg category-ratio scale (p=0.006) and modified Medical Research Council breathlessness scale (p=0.003), compared to patients without pneumonia. S (pO(2)) /F (IO(2)) ratio and PSI during SARS-CoV-2 pneumonia were directly associated with mid-term alteration of S (pO(2)) at rest (p<0.001) and during 6-min walk test (p<0.001), residual volume (p<0.001), total lung capacity (p<0.001 and p=0.003, respectively) and forced vital capacity (p=0.004 and p=0.03, respectively). CONCLUSION: Lung damage during COVID-19 correlates to the reduction of pulmonary function 4 months after acute infection. |*COVID-19[MESH] |*Quality of Life[MESH] |Humans[MESH] |Lung[MESH] |Respiratory Function Tests[MESH]Medium-term impact of COVID-19 on pulmonary function, functional capac(epmc).pdf DeepDyve Pubget Overpricing